UY31800A - Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb - Google Patents
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbbInfo
- Publication number
- UY31800A UY31800A UY0001031800A UY31800A UY31800A UY 31800 A UY31800 A UY 31800A UY 0001031800 A UY0001031800 A UY 0001031800A UY 31800 A UY31800 A UY 31800A UY 31800 A UY31800 A UY 31800A
- Authority
- UY
- Uruguay
- Prior art keywords
- erbb
- inhibitor
- cmet
- treatment method
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
La presente invención se refiere a un método para tratar cánceres en un paciente, que comprende administrar al paciente cantidades terapéuticamente eficaces de : a) un compuesto de fórmula A: o una sal farmacéuticamente aceptable del mismo, donde R1 -R4, p, y q son como se han definido; y (b) un inhibidor de erbB que inhibe el receptor erbB-1 o erbB-2 o erbB-3 o una combinación de los mismos. El método de la presente invención satisface la necesidad de la técnica con el descubrimiento de una terapia combinada que muestra indicios de ser más eficaz que las terapias descritas previamente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5032208P | 2008-05-05 | 2008-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31800A true UY31800A (es) | 2009-11-10 |
Family
ID=41257222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001031800A UY31800A (es) | 2008-05-05 | 2009-04-30 | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
Country Status (19)
Country | Link |
---|---|
US (3) | US20090274693A1 (es) |
EP (1) | EP2274304A4 (es) |
JP (1) | JP2011519941A (es) |
KR (1) | KR20110004462A (es) |
CN (1) | CN102083824A (es) |
AR (1) | AR071631A1 (es) |
AU (1) | AU2009244453B2 (es) |
BR (1) | BRPI0912582A2 (es) |
CA (1) | CA2723699A1 (es) |
CL (1) | CL2009001063A1 (es) |
EA (1) | EA020779B1 (es) |
IL (1) | IL209057A0 (es) |
MX (1) | MX2010012101A (es) |
PE (1) | PE20091832A1 (es) |
SG (1) | SG190623A1 (es) |
TW (1) | TW201006829A (es) |
UY (1) | UY31800A (es) |
WO (1) | WO2009137429A1 (es) |
ZA (1) | ZA201007722B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1948179A1 (en) | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
HUE025726T2 (en) | 2009-03-25 | 2016-04-28 | Genentech Inc | Anti-FGFR3 antibodies and their use |
HUE044629T2 (hu) | 2009-07-06 | 2019-11-28 | Boehringer Ingelheim Int | Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására |
TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
PT2719708T (pt) * | 2009-11-13 | 2018-01-16 | Daiichi Sankyo Europe Gmbh | Material e métodos para tratamento ou prevenção de doenças associadas a her-3 |
HUE057184T2 (hu) | 2010-07-16 | 2022-04-28 | Exelixis Inc | C-MET modulátor gyógyszerészeti készítmények |
CN103080134B (zh) | 2010-08-20 | 2015-11-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
AU2011307304C1 (en) | 2010-09-27 | 2016-10-20 | Exelixis, Inc. | Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
CN103384828A (zh) * | 2010-12-23 | 2013-11-06 | 雀巢产品技术援助有限公司 | 使用基于抗体的阵列进行恶性癌症疗法的药物选择 |
CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
GEP20217235B (en) | 2011-02-10 | 2021-03-25 | Inc Exelixis | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
KR20140025496A (ko) * | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
CA2848512A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
WO2013059788A1 (en) | 2011-10-20 | 2013-04-25 | Exelixis, Inc. | Process for preparing quinoline derivatives |
AR088872A1 (es) | 2011-11-14 | 2014-07-16 | Cephalon Inc | Derivados de uracilo como inhibidores de la quinasa axl y c-met |
JP6243345B2 (ja) * | 2011-12-05 | 2017-12-06 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
US8933103B2 (en) | 2012-01-31 | 2015-01-13 | Daiichi Sankyo Company, Limited | Pyridone derivatives |
EP2844254A1 (en) | 2012-05-02 | 2015-03-11 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
JP6389238B2 (ja) | 2013-03-15 | 2018-09-12 | エグゼリクシス, インコーポレイテッド | N−(4−{[6,7−ビス(メンチルオキシ)キノリン−4−イル]オキシ}フェニル)−n’−(4−フルオロフェニル)サイクロプロペイン−1,1−ジカルボキシアミドのメタボライト |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
AU2014334627B2 (en) * | 2013-10-14 | 2019-07-25 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
SG11201606413RA (en) | 2014-02-04 | 2016-09-29 | Astellas Pharma Inc | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
NZ725361A (en) | 2014-04-03 | 2022-09-30 | Merck Patent Gmbh | Combinations of cancer therapeutics |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
KR102634247B1 (ko) | 2014-08-05 | 2024-02-05 | 엑셀리시스, 인코포레이티드 | 다발성 골수종을 치료하기 위한 약물 병용물 |
JP6708130B2 (ja) | 2014-12-25 | 2020-06-10 | 小野薬品工業株式会社 | キノリン誘導体 |
FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
US10662235B2 (en) | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
CN110437145A (zh) * | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
WO2018111973A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
MY196680A (en) | 2017-01-26 | 2023-04-29 | Ono Pharmaceutical Co | Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2- pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3- quinolinecarboxamide |
MA47516A (fr) | 2017-02-15 | 2021-03-31 | Taiho Pharmaceutical Co Ltd | Composition pharmaceutique |
JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
CN114786682A (zh) | 2019-10-14 | 2022-07-22 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
ATE517091T1 (de) * | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
CA2633211A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
US20080058312A1 (en) * | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
CN105106199A (zh) * | 2006-12-14 | 2015-12-02 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
CA2683559C (en) * | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
WO2008143666A2 (en) * | 2007-05-17 | 2008-11-27 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CA2736563C (en) * | 2007-09-10 | 2016-01-26 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Application Discontinuation
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en active Application Filing
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130142790A1 (en) | 2013-06-06 |
CN102083824A (zh) | 2011-06-01 |
CA2723699A1 (en) | 2009-11-12 |
BRPI0912582A2 (pt) | 2015-07-28 |
TW201006829A (en) | 2010-02-16 |
SG190623A1 (en) | 2013-06-28 |
EA201071268A1 (ru) | 2011-06-30 |
EP2274304A1 (en) | 2011-01-19 |
CL2009001063A1 (es) | 2010-09-24 |
WO2009137429A1 (en) | 2009-11-12 |
AU2009244453B2 (en) | 2012-07-19 |
EP2274304A4 (en) | 2012-05-30 |
US20130150363A1 (en) | 2013-06-13 |
PE20091832A1 (es) | 2009-12-25 |
EA020779B1 (ru) | 2015-01-30 |
KR20110004462A (ko) | 2011-01-13 |
IL209057A0 (en) | 2011-01-31 |
US20090274693A1 (en) | 2009-11-05 |
MX2010012101A (es) | 2010-11-30 |
AU2009244453A1 (en) | 2009-11-12 |
JP2011519941A (ja) | 2011-07-14 |
ZA201007722B (en) | 2011-08-31 |
AR071631A1 (es) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31800A (es) | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
PA8740901A1 (es) | Compuestos organicos | |
CR20140410A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
HN2011000193A (es) | Derivados de piridazina como inhibidores de smo | |
DOP2012000243A (es) | Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales | |
CY1117200T1 (el) | Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος | |
EA201101507A1 (ru) | Способы лечения солидных опухолей | |
NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
EA201270247A1 (ru) | Способы применения с-мет-модуляторов | |
ECSP066457A (es) | 5-arilpirimidinas como agentes anti-cancer | |
EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
CR20120084A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα | |
DOP2023000285A (es) | Restos de administración terapéutica novedosos y usos de estos | |
MX2016001541A (es) | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20190503 |